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Pathophysiology

Neuroendocrine Responses to Acute Myocardial Infarction
Arlene B. Levine, MD,* and T. Barry Levine, MD*

A

myocardial infarcfion (MI) causesripplesacross an entire
physiologic stress response. A loss of myocardial blood
flow leads to regional myocardial necrosis. This in tum leads
to local ventricular abnormalities in contraction and relaxation
that compromi.se global cardiac function. The resultant hemodynamic derangements, such as a redistribution in cardiac output
and elevated filling pressures, lead to regional circulatory abnormalities and ultimately a neuroendocrine response. These
neuroendocrine responses to a MI are adaptive attempts to address the various aspects of the destabilizing events. Often these
changes are transient, normalizing with recovery. Although
potentially beneficial, the "overshoot" can participate in the
pathologic response, becoming part of the problem rather than
part of the solution. Injured endothelium releases endothelin, a
potent coronary and systemic vasoconstrictor. Myocardial injury triggers increased activity of both the sympathetic nervous
system and the renin-angiotensin system, and recent studies indicate that patient outcome may be predicted by the severity
of these neurohormonal responses. However, modification of
these responses may alter the clinical course of the underiying
disease process.
Theorefically, many factors participate in the increased neuroendocrine response to acute MI. Pain and anxiety increase
adrenomedullary release of epinephrine and norepinephrine.
Decreased cardiac output and hypotension stimulate peripheral
sympathetic activity and reduce renal blood flow, activating the
renin-angiotensin system. Regionally, myocardial necrosis releases norepinephrine stores from the infarcted area. Furthermore, coronary insufficiency resulting in ischemia but not necrosis also releases myocardial norepinephrine. The recent discovery of an intact renin-angiotensin system completely within
the heart raises the possibility of local activation of this endocrine system (I). The integrated action of these two systems on
the myocardium and peripherally may result in mutual stimulation. Likewise, coronary thrombosis and local hypoxia result in
release of the potent inotrope-vasoconstrictor endothelin. Furthermore, a persistent increase in circulating endothelin levels
has been seen with systemic hypoperfusion. Lastly, the increased atrial pressures accompanying an acute MI raise atrial
natruretic peptide production and release (Table 1). These alter-
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ations in the myocardial substrate lead to transient impairmeni
of the homeostatic baroreceptor regulation of cardiac function
(2).
There is considerable evidence for increased neuroendocrine
activity in both experimental infarction models and the clinical
setting of acute MI. A number of studies have shown that myocardial necrosis leads to release of norepinephrine stores in the
necrotic tissue (3-5). Infarction, however, is not a prerequisite
for this phenomenon. Muntz et al (6) evaluated alterations in
myocardial catecholamines during early ischemia in dogs. The
left anterior descending artery was ligated and regional release
of myocardial norepinephrine versus regional coronary blood
flow was assayed. At one hour after ligation, catecholamines
were identical in all regions ofthe myocardium. By three hours,
however, a significant decrease in catecholamines was noted in
the endocardium ofthe ischemic region. This was not seen in the
less ischemic pericardial region. The authors noted that there is
a redistribution of catecholamines from nerve terminals to other
interstitial tissue compartments.
Thus, ischemia prior to infarction results in release of myocellular norepinephrine to surrounding interstitial spaces. Potential toxic effects of excessive extracellular norepinephrine
are illustrated by observations of Gavras et al (7). Intravenous
infusions of norepinephrine in rabbits resulted in extensive, often confluent, multifocal myocardial necrosis.
Increased activity of the renin-angiotensin system is also seen
after a MI. Reduction in cardiac output resulting in decreased renal blood flow and renal perfusion pressure will increase the activity of this homeostatic system (8,9). Furthermore, increased
renal sympathetic nerve traffic will also increase renin release
(10). Finally, there is evidence that an intact renin-angiotensin
system exists within the heart. Ertl (11) has demonstrated that a
30-second occlusion of a coronary artery in dogs results in increased renin activily and angiotensin II levels. The increased
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Table 1
Neuroendocrine Changes in Acute Myocardial Infarction
Increased sympathetic tone
Activation ofthe renin-angiotensin-aldosterone system
Increased release of endothelin
Increased release of atrial natmretic peptide

vasoconstriction mediated by enhanced angiotensin 11 activity
results in increased afterload and thus myocardial oxygen demand, potentiating the left ventricular dysfunction seen in an
acute MI. Furthermore, the intriguing observation of Gavras et
al (7) that intravenous angiotensin II in rabbits caused extensive
myocardial necrosis identical to that seen with norepinephrine
raises the specter of further myocardial damage either directly or
mediated indirectly by norepinephrine.
Recentiy the vasoconstrictive inotropic peptide, endothelin,
has been isolated from the vascular endothelium of many species including man (12-14). Although the exact mechanisms
controlling its release are unclear, animal studies have shown
that thrombin formation and hypoxia, both seen in acute MI,
stimulate endothelin release (15,16). Infusions of this potent
coronary vasoconstrictor can result in further ischemia and infarct extension (17). One other potential action of endothelin is
stimulating the release of atrial natruretic factor (ANF) (18).
ANF is also released by the increased sympathetic tone and elevated atrial pressures seen with an acute Ml. In principle, this
vasodilator saluretic should counteract vasoconstrictor effects
of the other activated neuroendocrine mechanisms. ANF has a
physiologic role in normals but seems to be overwhelmed by the
increased activity of the sympathetic nervous system and reninangiotensin-aldosterone system.
There is considerable clinical evidence that increased neuroendocrine activity is detrimental to patients after a MI (Table 2).
These vasoconstrictor mechanisms increase myocardial oxygen
demand and reduce supply by vasoconstricting the coronary bed
and reducing blood flow. Therefore, they might be expected to
promote infarct expansion, recurrent ischemia, reinfarction,
heart failure, and arrhythmias. Early work was pertormed by
Prakash et al (19) measuring urinary catecholamines in patients
after acule MI. They demonstrated a correlation between neurohormonal activity and subsequent development of left ventricular failure, life-threatening arrhythmias, shock, and death.
In fact, those patients with complicated postinfarction courses
had significantly higher urinary catecholamines than patients
with uncomplicated MI. These early observations led to the concept that increased catecholamines were predictors of the severity of infarction and the clinical outcome. That this increased
sympathetic activity participated in the pathophysiology of
acute MI was brought into focus by Karlsberg et al (20). They
found increased levels of plasma norepinephrine and epinephrine within 4 hours of the onset of MI, prior to any creatine phosphokinase (CPK) release. There was a direct correlation between mean levels of epinephrine and norepinephrine, peak levels of epinephrine, and the levels of CPK generated by the MI.
During follow-up, those patients with high levels of circulating
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catecholamines were also those with the poorest prognosis. The
authors suggested that the magnitude of neurohormonal activation early in the course of an acute MI played a role in the extent
of myocardial damage and the eventual mortality. Vaney et al
(21) also demonstrated increased plasma norepinephrine and
epinephrine after MI. They, too, noted the correlation between
the size of the infarct and the levels of circulating catecholamines. Furthermore, they extended their observations to the
renin-angiotensin system, finding that plasma renin activity increased after MI. In their series, patients with the greatest increase in neuroendocrine activity after a Ml were those most
likely to develop cardiogenic shock or ventricular fibrillation.
Recentiy, Stewart et al (14) showed that persistently elevated
plasma endothelin levels also identified patients who had a more
complicated course and a worse prognosis.
Clearly, the larger the MI, the greater the neuroendocrine response and the worse the prognosis. However, the increased
neuroendocrine activity after an infarction can independently
contribute to infarct expansion and extension and worsening
prognosis.

Approaching a Myocardial Infarction
as "Telescoped Heart Failure"
One is struck by apparent pathophysiologic similarities of
acute MI and heart failure. In both situations pump dysfunction
is presenL Both heart failure and MI result in depleted myocardial catecholamine stores. Again in both, inappropriate peripheral vasoconstriction is mediated by increased activity of the
renin-angiotensin system and increased sympathetic tone. Finally, arrhythmias and sudden death are frequent occurrences in
both situations.
Thus, acute MI and stable heart failure may be viewed as a
physiologic continuum, and MI is essentially "telescoped heart
failure." This unifying physiologic outlook leads to potential
unification in therapy. In the clinical situation, therapy that benefits one disease seems to hold promise for the other.
Beta-blockade is an accepted therapy following MI. A number of placebo-controlled trials have shown that beta-blockade
improves survival and reduces reinfarction after a MI (22-24).
This observation was also underscored in the recent Thrombolysis in Myocardial Infarcfion (TIMI) phase II trial (25). In this
study, a subset of patients after thrombolytic therapy were randomized to metoprolol either immediately after infarction or six
days later. The results of this study showed that those receiving
metoprolol immediately postinfarction had a lower incidence of
reinfarction and recurrence of ischemia. Interestingly and analogously, there is increasing interest in the use of beta-blockade to
treat congestive heart failure (26). One randomized, placebocontrolled trial showed these drugs to improve patients with primary cardiomyopathy both functionally and symptomatically
(27). Why these drugs might benefit pafients with heart failure is
unknown. Perhaps beta-blockade protects myocardium from
further catecholamine mediated damage, or myocardial P-receptors may be "reset" leading to improved cardiac funcfion.
Angiotensin-converting enzyme inhibitors are accepted therapy for the treatment of heart failure (28-30). These drugs have
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Table 2
Physiologic Responses to Acute Myocardial Infarction Modulated by Neuroendocrine Activity
Sympathetic Nervous System

Renin-Angiotensin-Aldosterone

Cardiac Factors:
Increased chronotrophy
Increased inotrophy
Increased myocardial oxygen
consumption
Coronary vasoconstriction
Increased myocardial
ischemia and necrosis
Ventricular remodeling with
infarct explosion
Increased arrhythmogenesis

Increased chronotrophy
Increased inotrophy
Increased myocardial oxygen
consumption
Coronary vasoconstriction
Increased myocardial
ischemia and necrosis
Ventricular remodeling with
infarct explosion
Increased arrhythmogenesis

Coronary vasoconstriction
Increased inotrophy
Increased myocardial oxygen
consumption
Increa,sed myocardial ischemia
ANF release

Increased aortic impedance
Decreased venous
compliance
Redistribution of regional
blood tlow
Sodium retention/potassium loss
Stimulates SNS
Endothelin release (?)

Arterial vasoconstriction
Redistribution of regional
blood flow

Peripheral Effects:
Increased aortic impedance
Decreased venous
compliance
Redistribution of regional
blood flow
Stimulation of RAA system
Endothelin release (?)

Atrial Natruretic Factor

Endothelin

Increased renal sodium
excretion
Inhibition of SNS
and RAA

SNS = sympathetic nervous system, RAA = renin-angiolensin-aldosterone, ANF = atrial natruretic factor.

been shown to improve patients symptomatically and functionally and, more recently, to improve survival. The Cooperative
North Scandinavian Enalapril Survival Study utilized end-stage
congestive heart failure patients (31), most of whom had ischemia as the underlying etiology of their left ventricular dysfunction. The study showed patients randomized to enalapril had
significantiy greater six-month and one-year survival than those
patients receiving placebo. It has been shown experimentally
that a converting enzyme inhibitor preserves myocardial contractile function in an ischemic segment stressed by either
tachycardia or reperfusion (11). The ability of captopril to protect ischemic myocardium may represent a reduction in myocellular toxicity mediated by angiotensin II. In a recent study,
Pfefferet al (32) showed that patients randomized after MI to receive a converting enzyme inhibitor had increa,sed exercise capacity 3 to 12 months postinfarction when compared to a placebo-controlled cohort, this despite the presence of left ventricular dysfunction.
Thus, the lessons learned in the therapy of end-stage congestive heart failure appear to apply to acute Mls (telescoped congestive heart failure), and these preliminary studies offer an exciting promise to patients with ischemic heart disease. The ability to blunt the neurohormonal activity seen in an acute infarction promises to reduce complications and improve survival.
Aggressive pharmacological therapies are an essential and appropriate complement to the aggressive intervention strategies
pursued to treat MI.
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